Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Attachment disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Attachment disorder. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-000191-24 Sponsor Protocol Number: B4Z-UT-LYEL Start Date*: 2008-05-09
    Sponsor Name:Eli Lilly Nederland
    Full Title: An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003736 Attention deficit/hyperactivity disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005701-32 Sponsor Protocol Number: B4Z-IT-LYDS Start Date*: 2006-03-07
    Sponsor Name:ELI LILLY
    Full Title: An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions
    Medical condition: Child or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003736 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001288-58 Sponsor Protocol Number: 40122 Start Date*: 2012-05-21
    Sponsor Name:Academic Medical Center
    Full Title: Boosting oxytocin after trauma: The effects of intranasal oxytocin administration on emotional and motivational brain processes in PTSD
    Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10036316 Post-traumatic stress disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004177-83 Sponsor Protocol Number: 37202 Start Date*: 2011-11-14
    Sponsor Name:Academic Medical Center
    Full Title: Boosting the oxytocin system in acute trauma: The effectiveness of intranasal oxytocin treatments and stimulation of social support on preventing trauma related psychopathology
    Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10036316 Post-traumatic stress disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001767-11 Sponsor Protocol Number: B4Z-EW-LYFJ Start Date*: 2008-08-19
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...
    Medical condition: Attention Deficit/Hyperactivity Disorder/ADHD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003941-42 Sponsor Protocol Number: B4Z-SO-LY15 Start Date*: 2005-02-11
    Sponsor Name:Eli Lilly Sweden AB
    Full Title: A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that has its onset in childhood, and that is estimated to occur in 3% to 6% of school-age children. ADHD is characte...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004088-31 Sponsor Protocol Number: B4Z-XM-LYDM Start Date*: 2005-04-19
    Sponsor Name:Lilly S.A.
    Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp...
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000563-96 Sponsor Protocol Number: 0881A-101548 Start Date*: 2004-11-12
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHE...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) NO (Completed) FI (Completed) ES (Completed) AT (Completed) IE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000453-44 Sponsor Protocol Number: NL42746.058.12 Start Date*: 2013-06-19
    Sponsor Name:
    Full Title: The full scope of oxytocinergic influences on the parental brain: Maternal defensiveness and grandparent-child interactions
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005101-51 Sponsor Protocol Number: RIVM-V/330564/01 Start Date*: 2013-02-05
    Sponsor Name:National Institute of Health and the Environment (Dutch acronym: RIVM)
    Full Title: Tick Test & Prophylaxis Proof
    Medical condition: Lyme disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10025169 Lyme disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002111-41 Sponsor Protocol Number: AI438-047 Start Date*: 2015-05-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug...
    Medical condition: HIV, Adult
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) NL (Ongoing) GB (Completed) NO (Prematurely Ended) IE (Completed) PT (Completed) GR (Completed) FR (Completed) RO (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020404-29 Sponsor Protocol Number: H9V-MC-GFRF Start Date*: 2011-04-08
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 D...
    Medical condition: Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007672-41 Sponsor Protocol Number: Protocol B4Z-MC-LYDO Start Date*: 2008-12-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SE (Completed) AT (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000769-35 Sponsor Protocol Number: S61358 Start Date*: 2018-09-27
    Sponsor Name:University Hospital, KU Leuven
    Full Title: In search for an innovative neural marker and intervention for socio-communicative difficulties in children with and without autism spectrum disorders
    Medical condition: Autism Spectrum Disorders
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10003808 Autistic disorder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021215-16 Sponsor Protocol Number: H9P-MC-LNBQ Start Date*: 2011-02-17
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major De...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-021216-41 Sponsor Protocol Number: H9P-MC-LNBR(a) Start Date*: 2011-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005883-25 Sponsor Protocol Number: Scil-MD05-C02 Start Date*: 2007-04-25
    Sponsor Name:Scil Technology GmbH
    Full Title: Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison with Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    8.1 10034536 Periodontal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004333-33 Sponsor Protocol Number: EMN22/54767414AMY2005 Start Date*: 2019-07-08
    Sponsor Name:European Myeloma Network
    Full Title: Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis
    Medical condition: Patients with newly diagnosed stage 3B AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001962-13 Sponsor Protocol Number: AC-016-IT Start Date*: 2021-01-13
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis
    Medical condition: AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002667-28 Sponsor Protocol Number: 0974-031 Start Date*: 2008-05-29
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Wi...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) CZ (Completed) ES (Completed) AT (Completed) DK (Completed) FR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:39:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA